Avania, a medical tech contract research organization (CRO), announced its acquisition of MAXIS, a medical tech development service provider with expertise in pre-clinical engineering, design validation and verification, regulatory affairs, field services, and trial management.
What does the acquisition mean for Avania?
MAXIS has offices in San Jose, California, and Frankfurt am Main, Germany, with additional operational staff across the regions. With MAXIS, the combined organization offers unmatched high-touch strategic and operational expertise that uniquely drive results for medical device innovators and emerging original equipment manufacturers (OEMs).
“This acquisition strengthens our position as the leading MedTech focused CRO, advancing innovative medical tech from ideation to commercialization, providing highly customizable services in combination with robust global regulatory, clinical, and operational strategies to meet the unique needs of emerging OEMs,” said Sapna Hornyak, President and CEO, Avania.
“The addition of MAXIS furthers our strategy and will provide us with enhanced capabilities across a broader customer base as we continue to innovate and grow,” Sapna Hornyak said.
In addition, Avania customers will also benefit from an expanded roster of subject matter experts in the global pre-clinical, clinical (in vitro diagnostics, artificial intelligence/machine learning, and Software as Medical Device), and regulatory consulting space. Further, MAXIS bolsters the Avania depth across innovative technologies and multiple therapeutic areas.
What does the acquisition mean for MAXIS?
MAXIS clients will benefit from Avania’s extended global footprint, gaining access to the firm’s extensive network in the U.S., EU, and Australia. Additionally, Avania brings enhanced services to the combined companies — including biostatistics, data analytics, and medical writing.
Commenting on the acquisition, Kathleen Marshall, President of MAXIS Medical, said, “MAXIS’ long-standing commitment to emerging technology companies will be greatly enhanced with Avania’s sophisticated infrastructure and extensive resources. Avania’s understanding of our strategic value in the continuum of medical technology development was compelling and decisive, and we are delighted to be able to continue our mission with the Avania team.”
